Detalhe da pesquisa
1.
Applicability of probabilistic graphical models for early detection of SARS-CoV-2 reactive antibodies after SARS-CoV-2 vaccination in hematological patients.
Ann Hematol
; 101(9): 2053-2067, 2022 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-35780254
2.
One-year breakthrough SARS-CoV-2 infection and correlates of protection in fully vaccinated hematological patients.
Blood Cancer J
; 13(1): 8, 2023 01 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36599843
3.
Azacitidine vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the PETHEMA Registry.
Cancers (Basel)
; 14(9)2022 May 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35565471
4.
Use of Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia: The PETHEMA Registry Experience.
Cancers (Basel)
; 14(7)2022 Mar 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-35406512
5.
Real-life experience of venetoclax and hypomethylating agents in acute myeloid leukemia patients not candidates for intensive chemotherapy or who are refractory/relapsed: A single-centre experience.
Clin Case Rep
; 10(7): e6116, 2022 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-35898750
6.
Characteristics, clinical outcomes, and risk factors of SARS-COV-2 infection in adult acute myeloid leukemia patients: experience of the PETHEMA group.
Leuk Lymphoma
; 62(12): 2928-2938, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34292118